

Biocidal Products Committee

Work programme for BPC 2017 -2018 for active substance approvals

23 January 2017

1. Introduction

This document presents the work programme of the BPC constituting the rolling agenda for the WG and BPC meetings in 2017-2018. The current version contains the status as of 23 January 2017. This document lists the scheduled active substance product type (PT) combinations for which the evaluating Competent Authority (eCA) **confirmed** to the SECR to prepare the relevant documents in time and the preliminary scheduling of new active substances submitted under the BPR. The WG and BPC discussions for 2018 are pending the actual submission of the dossiers and the timelines to be established.

2. Planning for BPC and the WGs

In the tables below for each WG and BPC meeting (for each meeting also the process flow is indicated taken from the document "Timelines for the peer review of active substance evaluations" (published on the ECHA web-site at https://echa.europa.eu/documents/10162/4221979/revised_timeline_as_app_en.pdf/ba57583d-b081-4b6e-8632-3d8a5bfe0028) the following is presented:

- Active substance;
- Product type (PT);
- Evaluating Competent Authority (eCA);
- Submission differentiating between:
 - o CARs submitted for an active substance under the BPR;
 - o CARs submitted for a new active substance under the BPD;
 - o CARs submitted under the Review Programme before the entry into operation (EiO) 1 September 2013 of the BPR;
 - o CARs submitted under the Review Programme after the entry into operation (EiO) 1 September 2013 of the BPR;
- If the active substance meets the exclusion criteria according to the information in the CAR;
- If the active substance is a potential candidate for substitution according to the information in the CAR;
- If there is more than one applicant for an active substance PT combination: multiple dossier.

Reference is made to the working procedure for active substance approval which describes the principles for submission of CARs for the BPC work programme.

The schedule with respect to the CARs submitted for an active substance under the BPR is provisional pending a possible request for additional information by the eCA.

Working Group		16-20 January 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Propan-1-ol	1, 2, 4	DE	Review Programme; CAR submitted after EiO.
Imiprothrin	18	UK	Review Programme; CAR submitted before EiO.
Cholecalciferol	14	SE	New active BPD; CAR submitted after EiO.
Icaridin	19	DK	Review Programme; CAR submitted before EiO.

BPC-19		1-3 March 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Fludioxonil	7, 9, 10	DK	New active BPR.
Margosa extract	19	DE	Review Programme; CAR submitted after EiO.
Cypermethrin	18	BE	Review Programme; CAR submitted after EiO.
MIT	12	SI	Review Programme; CAR submitted after EiO.

Working Group		6-10 March 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Cyphenothrin	18	EL	Review Programme; CAR submitted after EiO.
Empenthrin	18	BE	Review Programme; CAR submitted before EiO.
MBO	2, 6, 11, 12 and 13	AT	Review Programme; CAR submitted after EiO.
HPT	2, 6, 11 and 13	AT	Review Programme; CAR submitted after EiO.

BPC-20		24-28 April 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Propan-1-ol	1, 2, 4	DE	Review Programme; CAR submitted after EiO.
Imiprothrin	18	UK	Review Programme; CAR submitted before EiO.
Cholecalciferol	14	SE	New active BPD; CAR submitted after EiO.
Icaridin	19	DK	Review Programme; CAR submitted before EiO.
(L)+ Lactic acid	2, 3, 4	DE	Review Programme; CAR submitted after EiO.
MBIT	6	PL	New active under BPD; CAR submitted after EiO.

Working Group		29 May-2 June 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Chlorophene	3,4	NO	Review Programme; submitted after EiO.
Sodium dichloroisocyanurate dihydrate	3, 4, 5	UK	Review Programme; CAR submitted after EiO.
Troclosene sodium	3, 4, 5	UK	Review Programme; CAR submitted after EiO.
Symclosene (trichloroisocyanuric acid)	3, 4, 5	UK	Review Programme; CAR submitted after EiO.
Azoxystrobin	7, 9, 10	UK	New active under the BPR.
d-Allethrin	18	DE	Review Programme; CAR submitted after EiO.
Esbiothrin	18	DE	Review Programme; CAR submitted after EiO.
PHMB (1415; 4.7)	1, 2, 4, 5 and 6	FR	Review Programme; CAR submitted after EiO.

BPC-21		26-30 June 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Cyphenothrin	18	EL	Review Programme; CAR submitted after EiO.
Empenthrin	18	BE	Review Programme; CAR submitted before EiO.
MBO	2, 6, 11, 12 and 13	AT	Review Programme; CAR submitted after EiO.
HPT	2, 6, 11 and 13	AT	Review Programme; CAR submitted after EiO.
Copper	2, 5, 11	FR	New active BPR.

Working Group		4-8 September 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sodium Cacodylate	18	PT	Review Programme; CAR submitted after EiO
Active chlorine generated from sodium chloride by electrolysis	1-5	SK	Review Programme; CAR submitted before EiO
Penflufen	8	UK	New Active under the BPR
Metofluthrin	19	UK	New active under BPD; CAR submitted after EiO.
Silver sodium hydrogen zirconium phosphate	4	SE	Review Programme; CAR submitted after EiO.
Silver copper zeolite	4, 5	SE	Review Programme; CAR submitted after EiO.
Silver	4, 5	SE	Review Programme; CAR submitted after EiO.
Silver zeolite	4, 5	SE	Review Programme; CAR submitted after EiO.
Amines, C10-16-alkyldimethyl, N-oxides	4	PT	Review Programme; CAR submitted after EiO
Chlorfenapyr	18	PT	Review Programme; CAR submitted after EiO.
Lavandin oil	19	PT	Review Programme; CAR submitted after EiO
Phenoxyethanol	1, 2, 4	UK	Review Programme; CAR submitted after EiO
Prallethrin	18	EL	Review Programme; CAR submitted before EiO.
Pentapotassium bis(peroxymonosulphate) bis(sulphate) (KMPS)	2-5	SI	Review Programme; CAR submitted after EiO
<i>Willaertia subsp. magna, C2c.Maky</i>	11	FR	New Active BPR.
Peroxyoctanoic acid	3, 4	FR	Review Programme; CAR submitted after EiO
Salicylic acid	2, 3, 4	NL	Review Programme; CAR submitted after EiO.

BPC-22		2-6 October 2017	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Chlorophene	3,4	NO	Review Programme; CAR submitted after EiO
Sodium dichloroisocyanurate dehydrate	3, 4, 5	UK	Review Programme; CAR submitted after EiO
Troclosene sodium	3, 4, 5	UK	Review Programme; CAR submitted after EiO
Symclosene (trichloroisocyanuric acid)	3, 4, 5	UK	Review Programme; CAR submitted after EiO
Azoxystrobin	7, 9, 10	UK	New active under the BPR
d-Allethrin	18	DE	Review Programme; CAR submitted after EiO.
Esbiothrin	18	DE	Review Programme; CAR submitted after EiO.
PHMB (1415; 4.7)	1, 2, 4, 5 and 6	FR	Review Programme; CAR submitted after EiO.

Working Group	WG V 2017		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sulphur dioxide generated from sulphur by combustion	4	DE	Review Programme; CAR submitted after EiO.
SO ₂ in-situ generated from sodium metabisulfite	9	DE	New active BPR.
DBNPA	4	DK	Review Programme; CAR submitted after EiO.
ADBAC	3, 4	IT	Review Programme; CAR submitted before EiO.
Bardap 26	4	IT	Review Programme; CAR submitted before EiO.
DDAC	3, 4	IT	Review Programme; CAR submitted before EiO.
ADBAS	4	MT	Review Programme; submitted before EiO
Diamine	8	PT	Review Programme; CAR submitted before EiO.

BPC-23	11-15 December 2017		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sodium Cacodylate	18	PT	Review Programme; CAR submitted after EiO
Active chlorine generated from sodium chloride by electrolysis	1-5	SK	Review Programme; CAR submitted before EiO
Penflufen	8	UK	New Active under the BPR
Metofluthrin	19	UK	New active under BPD; CAR submitted after EiO.
Silver sodium hydrogen zirconium phosphate	4	SE	Review Programme; CAR submitted after EiO.
Silver copper zeolite	4, 5	SE	Review Programme; CAR submitted after EiO.
Silver	4, 5	SE	Review Programme; CAR submitted after EiO.
Silver zeolite	4, 5	SE	Review Programme; CAR submitted after EiO.
Silver zinc zeolite	4		Review Programme; CAR submitted before EiO
Amines, C ₁₀ -16-alkyldimethyl, N-oxides	4	PT	Review Programme; CAR submitted after EiO
Chlorfenapyr	18	PT	Review Programme; CAR submitted after EiO.
Lavandin oil	19	PT	Review Programme; CAR submitted after EiO
Phenoxyethanol	1, 2, 4	UK	Review Programme; CAR submitted after EiO
Mixture of cis- and trans- <i>p</i> -menthane-3,8 diol (PMDRBO)	19	UK	Review Programme; CAR submitted after EiO.
Prallethrin	18	EL	Review Programme; CAR submitted before EiO.
Pentapotassium bis(peroxymonosulphate) bis(sulphate) (KMPS)	2-5	SI	Review Programme; CAR submitted after EiO.
<i>Willaertia subsp. magna</i> , C2c.Maky	11	FR	New Active under the BPR.
Peroxyoctanoic acid	3, 4	FR	Review Programme; CAR submitted after EiO
Salicylic acid	2, 3, 4	NL	Review Programme; CAR submitted after EiO.

Working Group	WG I 2018		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Hydrogen peroxide	11, 12	FI	Review Programme; CAR submitted after EiO.

BPC-24	2018		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sulphur dioxide generated from sulphur by combustion	4	DE	Review Programme; CAR submitted after EiO.
SO ₂ in-situ generated from sodium metabisulfite	9	DE	New active BPR.
DBNPA	4	DK	Review Programme; CAR submitted after EiO.
ADBAC	3, 4	IT	Review Programme; CAR submitted before EiO.
Bardap 26	4	IT	Review Programme; CAR submitted before EiO.
DDAC	3, 4	IT	Review Programme; CAR submitted before EiO.
ADBAS	4	MT	Review Programme; CAR submitted before EiO.

Working Group	WG II 2018		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Ethanol	1, 2, 4	EL	Review Programme; CAR submitted before EiO.
Monolinuron	2	UK	Review Programme; CAR submitted after EiO.
Cinnamic aldehyde	2	UK	Review Programme; CAR submitted after EiO.
Glycolic acid	2, 3, 4	NL	Review Programme; CAR submitted after EiO.
Pyrethrins and Pyrethroids	18, 19	ES	Review Programme; CAR submitted before EiO.
Chrysanthemum cinerariaefolium	18	ES	Review Programme; CAR submitted before EiO.

BPC-25	2018		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Hydrogen peroxide	11, 12	FI	Review Programme; CAR submitted after EiO.

Working Group	WG-III 2018		
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Glucoprotamin	2, 4	DE	Review Programme; CAR submitted after EiO
d-Tetramethrin	18	DE	Review Programme; CAR submitted after EiO.
Tetramethrin	18	DE	Review Programme; CAR submitted after EiO.

BPC-26		2018	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Ethanol	1, 2, 4	EL	Review Programme; CAR submitted before EiO.
Monolinuron	2	UK	Review Programme; CAR submitted after EiO.
Cinnamic aldehyde	2	UK	Review Programme; CAR submitted after EiO.
Glycolic acid	2, 3, 4	NL	Review Programme; CAR submitted after EiO.
Pyrethrins and Pyrethroids	18, 19	ES	Review Programme; CAR submitted before EiO.
Chrysanthemum cinerariaefolium	18	ES	Review Programme; CAR submitted before EiO.

Working Group		WG-V 2018	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sodium dichloroisocyanurate dihydrate	2	UK	Review Programme; CAR submitted after EiO.
Troclosene sodium	2	UK	Review Programme; CAR submitted after EiO.
Symclosene (Trichloroisocyanuric acid)	2	UK	
Bardap 26	2	IT	Review Programme; CAR submitted before EiO
ADBAS	2	MT	Review Programme; CAR submitted before EiO

BPC-27		2018	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Glucoprotamin	2, 4	DE	Review Programme; CAR submitted after EiO
d-Tetramethrin	18	DE	Review Programme; CAR submitted after EiO.
Tetramethrin	18	DE	Review Programme; CAR submitted after EiO.

Working Group		WG-V 2018	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>

BPC-28		2018	
<i>Active substance</i>	<i>PT</i>	<i>eCA</i>	<i>Submission</i>
Sodium dichloroisocyanurate dihydrate	2	UK	Review Programme; CAR submitted after EiO.
Troclosene sodium	2	UK	Review Programme; CAR submitted after EiO.
Symclosene (Trichloroisocyanuric acid)	2	UK	
Bardap 26	2	IT	Review Programme; CAR submitted before EiO
ADBAS	2	MT	Review Programme; CAR submitted before EiO